Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials

Pancreas

Volumn 39, Issue 7, 2010, Pages 967-971

  El Rayes, Bassel F ^a   Jasti, Pallavi ^a   Severson, Richard K ^b   Almhanna, Khaldoun ^a   Philip, Philip A ^a   Shields, Anthony ^a   Zalupski, Mark ^c   Heilbrun, Lance K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

clinical trials participation; disparities; pancreas cancer; race

Indexed keywords

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CENTER; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; RACE; SOCIAL STATUS; STATISTICAL SIGNIFICANCE;

AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PATIENT PARTICIPATION; SOCIAL CLASS;

EID: 77957342589     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181da91dd     Document Type: Article

References (25)

1. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291: 2720-2726.
2. Adsay NV, El-Rayes BF, Philip PA. Pancreatic cancer: the evolving role of systemic therapy. Expert Opin Pharmacother. 2001;2: 1939-1947.
3. Gross CP, Filardo G, Mayne ST, et al. The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer. 2005;103:483-491.
4. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
5. Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88: 812-816.
6. Harper S, Lynch J, Meersman SC, et al. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev. 2009;18:121-131.
7. Zalupski MM, Philip PA, LoRusso P, et al. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother Pharmacol. 1997;40:225-227.
8. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
9. Al-Sukhun S, Zalupski MM, Ben-Josef E, et al. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. Am J Clin Oncol. 2003;26:543-549.
10. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92:569-577.
11. El-Rayes BF, Zalupski MM, Shields AF, et al. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol. 2003;21:2920-2925.
12. Lee E. Statistical Methods for Survival Data Analysis. 3rd ed. New York, NY: Wiley & Sons, Inc; 2003.
13. Allison P. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, Inc; 1995.
14. US Census Bureau. Available at: http://www.census.gov/main/www/cen2000. html. Washington, DC: US Census Bureau; 2000. Accessed June 15, 2009.
15. Stewart JH, Bertoni AG, Staten JL, et al. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14:3328-3334.
16. Cross CK, Harris J, Recht A. Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies. Cancer. 2002;95:1988-1999.
17. Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004;22:730-734.
18. Mouton CP, Harris S, Rovi S, et al. Barriers to black women's participation in cancer clinical trials. J Natl Med Assoc. 1997;89:721-727.
19. Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19:1728-1733.
20. Gross CP, Herrin J, Wong N, et al. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol. 2005;23:4755-4763.
21. Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004;199:644-651.
22. Simon MS, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004;22:2046-2052.
23. Verhoef C, van de Weyer R, Schaapveld M, et al. Better survival in patients with esophageal cancer after surgical treatment in university hospitals: a plea for performance by surgical oncologists. Ann Surg Oncol. 2007;14:1678-1687.
24. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777-783.
25. Schrag D, Earle C, Xu F, et al. Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst. 2006;98:163-171.